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Abstract
Background: Central nervous system (CNS) exposure to HIV is a universal facet of systemic infection.
Because of its proximity to and shared barriers with the brain, cerebrospinal fluid (CSF) provides a useful
window into and model of human CNS HIV infection.
Methods: Prospective study of the relationships of CSF to plasma HIV RNA, and the effects of: 1)
progression of systemic infection, 2) CSF white blood cell (WBC) count, 3) antiretroviral therapy (ART),
and 4) neurological performance. One hundred HIV-infected subjects were cross-sectionally studied, and
28 were followed longitudinally after initiating or changing ART.
Results: In cross-sectional analysis, HIV RNA levels were lower in CSF than plasma (median difference
1.30 log10 copies/mL). CSF HIV viral loads (VLs) correlated strongly with plasma VLs and CSF WBC counts.
Higher CSF WBC counts associated with smaller differences between plasma and CSF HIV VL. CSF VL did
not correlate with blood CD4 count, but CD4 counts <50 cells/µL associated with a low prevalence of
CSF pleocytosis and large differences between plasma and CSF VL. CSF HIV RNA correlated neither with
the severity of the AIDS dementia complex (ADC) nor abnormal quantitative neurological performance,
although these measures were associated with depression of CD4 counts.
In subjects starting ART, those with lower CD4 counts had slower initial viral decay in CSF than in plasma.
In all subjects, including five with persistent plasma viremia and four with new-onset ADC, CSF HIV
eventually approached or reached the limit of viral detection and CSF pleocytosis resolved.
Conclusion: CSF HIV infection is common across the spectrum of infection and is directly related to CSF
pleocytosis, though whether the latter is a response to or a contributing cause of CSF infection remains
uncertain. Slowing in the rate of CSF response to ART compared to plasma as CD4 counts decline
indicates a changing character of CSF infection with systemic immunological progression. Longer-term
responses indicate that CSF infection generally responds well to ART, even in the face of systemic
virological failure due to drug resistance. We present simple models to explain the differing relationships
of CSF to plasma HIV in these settings.
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Frequent abnormalities in cerebrospinal fluid (CSF),
including increased white blood cells (WBCs), were recog-
nized early in the AIDS epidemic, not only in patients
examined toward the end of their course who suffered
neurological complications [1], but also in those systemi-
cally and neurologically asymptomatic [2,3]. Indeed,
these observations were among the first indicators that the
central nervous system (CNS) is an early and common tar-
get of systemic HIV infection. While initial studies apply-
ing quantitative HIV RNA measurements to the CSF
suggested correlation between the CSF HIV RNA (viral
load, VL) and the AIDS dementia complex (ADC) [4],
subsequent reports have shown that HIV can be found in
the CSF throughout the course of infection, beginning
with primary infection [5], and that other factors, includ-
ing the progression of immune dysfunction, are likely
important in the development of ADC [6-8]. This has
raised the fundamental question of why HIV causes brain
dysfunction, manifesting as ADC, only late in the course
of infection and only in some individuals [9]. Addition-
ally, because the brain and CSF are separated from the
blood by barriers to the transfer of virus, immune
defenses and antiviral drugs, there has been considerable
concern as to whether local infection in these 'compart-
ments' might be isolated from host defenses and antiviral
therapy (ART), leading to both viral persistence and local
selection of resistance [10-12]. While CSF and brain infec-
tions by HIV are not identical, examination of this easily
sampled fluid provides a window into CNS infection [13].
In order to better interpret CSF findings, it is essential to
understand what factors contribute to elevated CSF HIV
RNA concentrations. How do systemic infection and its
progressive damage to the immune system affect the VL in
a non-lymphatic compartment like the CSF space? How
does CSF infection respond to ART? What is the origin and
importance of the CSF cell reaction detected as CSF lym-
phocytic pleocytosis and how does this cell reaction
respond to ART? What is the effect of ART on neurological
function in subjects presenting with ADC?
To address these questions and better understand the rela-
tionship of the CSF HIV RNA levels to other aspects of
infection and clinical findings, we undertook a prospec-
tive study of CSF in a broad range of HIV-infected subjects
using two complimentary approaches. The first involved
cross-sectional analysis of a clinically diverse subject sam-
ple. The second longitudinally followed subjects initiating
ART. In addition to its direct clinical implications, this
longitudinal approach used treatment as an 'experimen-
tal' intervention to dissect dynamic aspects of the relation-
ships among these study variables.
Methods
Subjects and Protocols
One-hundred subjects were entered into these studies
between November, 1996 and June, 2001 in the context
of protocols approved by the University of California, San
Francisco (UCSF) Committee on Human Research
(CHR); follow-up on a few continued until December
2004. Informed consent was obtained from all subjects.
In the case of one subjects with ADC, consent was also
obtained from his sister with durable power of attorney.
Subjects were excluded if they suffered HIV-related or
other active CNS diseases except ADC. The cross-sectional
analysis targeted a total of 100 subjects, including the
baseline observations of subjects starting treatment, along
with a previously-reported group who stopped treatment
[14,15]. Subjects were clinically stable with the exception
of six presenting with a new diagnosis or progression of
ADC at the time of study entry.
Treatment decisions were independent of this CSF study.
New therapies (either starting de novo or representing a
change of drugs) were prescribed by subjects' primary
care-giver or determined by another clinical trial. Excep-
tions were five subjects who entered an open-label study
of high-dose abacavir (600 mg twice daily) which was
completed before abacavir was licensed for clinical use
[16,17]. The first subject in this small protocol substituted
abacavir for one of the drugs in his existing regimen, while
the remaining subjects began this nucleoside reverse tran-
scriptase inhibitor (nRTI) in the context of novel combi-
nation ART. Treatment protocols sought to enter subjects
with and without ADC, and with plasma VLs ≥ 50,000
HIV RNA copies/mL (cpm), although exceptions were
made to this virological entry criterion. Baseline lumbar
punctures (LPs) were performed within one week before
initiating ART and carried forward as time zero. Most sub-
jects underwent their initial 4–5 LP on-drug studies dur-
ing the first month, with later assessments at
approximately 3 and 6–12 months and then one to three
times yearly thereafter.
LP and CSF analysis
CSF was obtained for study purposes rather than for clin-
ical diagnosis and was processed in standardized fashion
as previously described [18,14]. CSF and plasma from
each visit were analyzed for HIV RNA concurrently. At the
time of the first LP, CSF was also analyzed for neurosyph-
ilis (VDRL) and cryptococcal antigen (all negative). CSF
cell counts, differential, protein and albumin levels along
with measurement of blood albumin and CD4+ and
CD8+ T lymphocyte counts by flow cytometry were per-
formed using routine clinical methods in the San Fran-
cisco General Clinical Laboratory.Page 2 of 19
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Table 1: Baseline Characteristics of Study Subjects, including subgroups.
Sex: HIV-1 RNA
N Age M:F CD4+ Duration of Infectiona CDC Stage C3b ADC Stage QNPZ-4 Score Plasma CSF P-C log10 Diff. CSF WBC
(yrs) (ratio) (cells/mm3) (mean yrs +/- SD) (percent) (log10RNA copies/mL) (cells/mm3)
Total 100 39.0 
(36.0–45.0)
91:9 181.5 
(48.8 – 285.3)
9.7 
(+/- 5.60)
70.3% 0 
(0 – 1)
-0.50 
(-1.53 – 0.21)
4.73 
(3.52 – 5.15)
2.74 
(1.48 – 4.00)
1.30 
(0.19 – 2.32)
1.0 
(0.0 – 4.0)
ADC ≥ 1 = 30.0%
Subdivision by Treatment Group and Effect
Off Treatment
46 38.0 
(33.5 – 43)
42:4 195.0 
(33.5 – 307.5)
7.5 
(+/- 5.80)
65.2% 0 
(0 – 0.5)
-0.46 
(-1.35 – 0.26)
4.93 
(4.53 – 5.49)
3.61 
(2.57 – 4.40)
1.19 
(0.42 – 21.7)
2.0
(0 – 11.3)
ADC ≥ 1 = 23.1%
On Treatment (Total)
54 43.0 
(38.0-29.3)
49:5 181.5 
(76.0 – 275.5)
11.09 
(+/- 5.08)
75.9% 0.5 
(0 – 1.0)
-0.51 
(-2.62 – 0.20)
3.40 
(1.85 – 4.80)
1.66 
(1.28 – 3.07)
1.37 
(0.0 – 2.42)
1.0 (0.0 – 2.0)
ADC ≥ 1 = 36.6%
On Treatment Failures
36 40.0 
(38.0 – 47.8)
32:4 166.5 
(48.3 – 276.5)
11.24 
(+/- 4.18)
75.0% 0.5 
(0 – 1.0)
-0.42 
(-2.40 – 0.25)
4.73 
(3.99 – 5.04)
2.45 
(1.45 – 3.64)
2.19 
(1.29 – 2.59)
0.5 (0.0 – 2.8)
ADC ≥ 1 = 37.0%
Values are medians with IQR in parentheses beneath, unless noted. P-Clog10 Diff. is the difference in plasma and CSF log10 HIV concentrations.
aData available for 49 of the 100 subjects.
bData available for 81 of the 100 subjects; categorization based on the 1993 Centers for Disease Control HIV classification system.
BMC Infectious Diseases 2005, 5:98 http://www.biomedcentral.com/1471-2334/5/98Clinical evaluation
Each subject had a baseline clinical evaluation, which
included a general and neurological assessment and med-
ical history review; none had current or prior cryptococcal
meningitis or any other opportunistic neurological disor-
der. If indicated by neurological symptoms or signs, sub-
jects had neuroimaging studies to assess for confounding
conditions. Subjects underwent a standardized, ADC-
focused neurological evaluation leading to ADC diagnosis
and staging [19-22]. Diagnosis of ADC conformed to cri-
teria for the AIDS-related cognitive/motor complex out-
lined by the American Academy of Neurology Task Force
[23]. In the presence of any static neurological condition
that might interfere with designation of AIDS related cog-
nitive or motor dysfunction (for example, prior head
trauma or psychiatric diagnosis), no ADC scale was
assigned. Subjects underwent brief quantitative perform-
ance testing with a battery of four tasks (timed gait, finger
tapping with the dominant hand, grooved pegboard
placement with the non-dominant hand, and Digit Sym-
bol test from the WAIS-R) yielding a combined normal-
ized score derived from the mean of individual Z-scores,
the quantitative neurological performance Z-score on four
tests (QNPZ-4 score), as previously described [24,20,22].
Virological methods
HIV RNA was measured in cell-free CSF and plasma by the
Roche Amplicor Monitor assay (versions 1.0 and 1.5,
Roche Diagnostic Systems, Inc., Branchburg, N.J) using
the standard and Ultrasensitive extraction methods. The
latter has a quantitation limit of 50 and a detection limit
of approximately 20 HIV RNA cpm. We used results in the
range of 20 – 50 cpm for data reporting and analysis, and
assigned a default 'floor' value of 19 (log10 1.28) cpm for
values below the detection limit. Concurrent paired CSF
and plasma samples were treated identically and run at
the same time. HIV RNA concentrations were transformed
to log10 values for all analysis. Because limited serial sam-
pling during the acute phase of treatment-induced viral
decay precluded complex modeling, estimates of acute-
phase HIV-RNA half-lives were derived by assuming sim-
ple exponential decay during an initial phase (days 0 –
11) as previously described [25]. While the acute phase of
plasma viral decay is shorter than 11 days, we used this
extended period for rough comparison because of the lim-
ited sampling in some subjects. The acute decay rate, λ, for
each subject was estimated by least-square regression of
measurement time (including baseline) on a subject's
log10 HIV-RNA values. The subject's acute-phase HIV-RNA
half-life was log102/λ.
Antiretroviral drug resistance
Antiretroviral drug resistance was assessed by both pheno-
typic and genotypic methods in selected subjects using the
PhenoSense™ HIV assay (ViroLogic Inc., South San Fran-
Baseline distributions of HIV concentrations and CSF WBCs in r ation to lood CD4 cell counts in the 100 subjects ana-lyzed cr ss-secti nallyFigure 1
Baseline distributions of HIV concentrations and CSF WBCs 
in relation to blood CD4 cell counts in the 100 subjects ana-
lyzed cross-sectionally. Individual panels show: (A) plasma 
HIV RNA, (B) CSF HIV RNA, and (C) CSF WBC counts in 
relation to blood CD4 counts. The vertical dotted lines in 
each panel separate the subjects into blood CD4 quartiles. 
The Symbol key appears in the bottom right panel, red boxes 
indicate patients off treatment, while blue circles indicate 
those on treatment.
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BMC Infectious Diseases 2005, 5:98 http://www.biomedcentral.com/1471-2334/5/98cisco, CA) to analyze functional susceptibility in a recom-
binant assay and mutations in the reverse transcriptase
(RT) and protease (PR) regions [26]. Phenotypic suscepti-
bility results were reported as fold-change in the 50%
inhibition concentration (IC50) relative to a wild-type
virus reference standard, while genotypic analysis com-
pared RT and PR sequences in the blood or CSF HIV pop-
ulations to the reference wild-type (e.g., NL4-3).
Statistical analysis
Because of the skewed distributions of several study varia-
bles, unless otherwise indicated, the median and inter-
quartile range (IQR; 25th percentile – 75th percentile)
were used for descriptive statistics, and nonparametric
tests were used for comparisons. In the cross-sectional
analysis, all p-values were two-sided, with p-values < 0.01
considered significant. Statistics were performed using
SPSS 11.5 (SPSS Inc., Chicago, IL), or Prism 4.0 (Graph-
Pad Software Inc, San Diego, CA).
Results
Study subject demographics
Of the 100 subjects in the cross-sectional study, 65 were
recruited into a cross-sectional only group and studied
only once, 26 were in a longitudinal treatment group and
were followed with serial LPs, and nine subjects were in a
longitudinal Structured Treatment Interruption (STI)
group and are reported elsewhere [14,15]. However, as
two of these nine STI group subjects were studied after
they restarted treatment, they were also included among
the longitudinal treatment group, bringing the total
number of patients in the longitudinal treatment group to
28. Table 1 provides a summary of the salient clinical and
laboratory variables in the 100 subjects and also divides
them according to ART treatment status. Additionally,
Table 1 summarizes data from a subgroup of patients on
ART who were considered treatment failures, as defined
by plasma HIV RNA concentration >500 RNA cpm.
Reflecting the demography of the local epidemic, over 90
percent of our subjects were men, with a median age of 39
years. The majority of the cross-sectional only sample was
on ART, though VL was undetectable in plasma in only
eight of these 65 subjects, reflecting a bias toward entry of
subjects with virological failure.
While most of the 28 subjects in the longitudinal treat-
ment group were ART-naive or had limited prior therapy,
seven were on therapy, changing or adding one or more
drugs at baseline. Twenty-four of 80 subjects without con-
founding neurological conditions (30%) were diagnosed
with ADC: 13 subjects with ADC Stage 1, 8 subjects with
ADC Stage 2, and 3 subjects with ADC Stage 3. Most had
stable neurological impairment and clinically 'inactive'
CNS disease (exceptions are discussed below). The preva-
lence of ADC was the principal reason for the overall
median QNPZ-4 score below "normal".
Cross-sectional analysis
CSF HIV RNA
In the cross-sectional evaluation, HIV RNA was character-
istically lower in CSF than in plasma, and the VL differ-
ences between the two compartments, which we express
here and below as the ∆Plasma:CSF (log10 plasma HIV
RNA – log10 CSF HIV RNA), varied widely, ranging from -
1.32 to 4.08 log10 cpm (Table 1). CSF VL was higher than
plasma VL in only 11 of 100 subjects, with a difference of
>0.50 log10 cpm found in only 3 of these 11 subjects. Fig-
ure 1 shows the distribution of the plasma (A) and CSF
(B) HIV RNA in relation to the blood CD4 cell counts in
the 100 subjects. Division of the results into CD4 quartiles
shows that the cohort did not distribute evenly among
CD4 values, so that one quarter of the subjects had CD4
counts below 49 cells/µL.
The treated subjects had lower VLs in both compartments
(Table 1, Figure 1; p < 0.001 for both; Kruskal-Wallis test).
To assess the effects of ART on CSF HIV in the setting of
treatment failure, we analyzed the results in the subjects
on ART who had plasma HIV VLs above 500 cpm and
include this subgroup in Table 1. The median plasma VL
in this subgroup was similar to that of the off treatment
group, though these groups differed statistically (p =
0.017, Mann-Whitney). More notably, the median CSF
values differed by more than 10-fold (p = 0.001), and
therefore the median ∆Plasma:CSF of the failure group
was greater than the median for subjects off treatment.
This post hoc analysis raises the question of whether 'failed'
treatment might alter the relationship of CSF to plasma
HIV, and indicates that despite plasma HIV escape, treat-
ment still had an effect on CSF.
Overall, CSF HIV RNA correlated with only two other var-
iables examined, the plasma VL and the CSF WBC count
(p < 0.001 for both, Spearman's rho 0.629 and 0.516,
respectively). In contrast, CSF HIV did not correlate with
the blood CD4+ cells, ADC stage or QNPZ-4 scores. How-
ever, as shown on Figure 1, plasma VLs were highest in
subjects in the first CD4 quartile (<49 cells/µL). The
plasma VL in this quartile was 5.03 log10 cpm with IQR
4.67 – 5.57, while the median plasma VL of the remaining
75 subjects was 4.35 log10 cpm with IQR 2.92 to 4.98 (p =
0.001). In contrast, the CSF VLs of subjects in this first
quartile (median 2.75 log10 cpm, IQR 2.15 – 3.20) did not
differ from those of the remaining 75 subjects (median
2.64 log10 cpm, IQR 1.28 – 4.19) (p = 0.650). The com-
bined effect of higher plasma VL and similar CSF VL in the
first quartile compared to the other subjects resulted in a
greater median ∆Plasma:CSF for subjects in the first quar-
tile (2.25 log10 cpm, with IQR 1.75 – 2.95), relative to thePage 5 of 19
(page number not for citation purposes)
BMC Infectious Diseases 2005, 5:98 http://www.biomedcentral.com/1471-2334/5/98median for the remaining 75 subjects (0.800 log10 cpm,
IQR of 0.00 – 1.97) (p = 0.001).
CSF WBC counts
Twenty-four subjects had abnormal CSF WBC counts (>5
cells/µL), composed of 85–100 percent lymphocytes, with
the remainder mononuclear cells. All 24 were asympto-
matic, despite a median count of 15 cells/µL (IQR 9 – 32
cells/µL, range 6 – 66 cells/µL). The CSF WBC count did
not significantly correlate with plasma VL.
Figure 2 shows the relationship between CSF WBC count
and plasma and CSF HIV VLs using a three-dimensional
plot. The highest CSF VLs were in subjects with both pleo-
cytosis and high plasma VLs (generally ≥ 4.0 log10 cpm).
These were also the subjects with the highest CSF VLs. By
contrast, many subjects with similarly high plasma VLs
without pleocytosis had lower CSF VLs. Three subjects with
CSF VLs that substantially exceeded those of plasma are
indicated by subject number in Figure 2 and are discussed
below. Subjects with CSF WBC counts ≥ 10 cells/µL had a
median VL difference between the two fluids of 0.150
log10 cpm (IQR -0.115 – 0.425 copies) – far below the dif-
ference seen in the group overall.
CSF WBC counts showed only a modest correlation with
CD4 counts (p = 0.01; rho 0.254), Figure 1C shows that
this correlation related chiefly to differences between the
subjects in the lowest CD4 quartile (less than 50 cells/µL)
and the remaining subjects with higher CD4 counts. The
median WBC count for first quartile was 0 cells/µL (IQR 0
Three-dimensional plot showing relationships among plasma and CSF HIV RNA concentrations and CSF WBC countsFigure 2
Three-dimensional plot showing relationships among plasma and CSF HIV RNA concentrations and CSF WBC counts. Subjects 
with CSF pleocytosis had highest CSF VLs. In turn, higher CSF VLs were noted chiefly in those with elevated plasma HIV 
(>10,000 cpm). The numbers near three of the data points identify the three subjects with substantially higher CSF than plasma 
HIV RNA (see text).
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BMC Infectious Diseases 2005, 5:98 http://www.biomedcentral.com/1471-2334/5/98– 1.0) while that for the remaining subjects was 2.0 cells
(IQR 0 – 8.3 cells) (p = 0.009; t-test).
Neurological status
Neither the ADC stage nor the QNPZ-4 score correlated
with the CSF or plasma VLs across the cross-sectional
group, though these two measures correlated strongly
with each other (p < 0.001, rho -0.746), and both also cor-
related with the CD4 count (p < 0.001 for both, rho = -
0.515 for ADC stage and 0.467 for QNPZ-4). For all ADC
subjects, the CD4 median was 67.5 cells/µL (IQR 28.0 –
124.5); for the untreated ADC subgroup, the median was
35 (IQR 14.5 – 67.5) cells/µL, and for those on ART, the
median was 95 cells/µL (IQR 36 – 205).
Only 6 subjects were judged to have active ADC. Two of
these were treatment failures with active disease despite
ART, while the other four were off ART at presentation.
Among the six were the three subjects designated as out-
liers in Figure 2 because of VLs higher in CSF than in
plasma: subject 4034 with ADC Stage 1, and subjects 4032
and 4033 with Stage 2. While two had elevated CSF WBC
counts consistent with the general positive correlation
between of high CSF VL and CSF WBC count, subject 4032
did not. His CSF VL was high (19,700 cpm), his plasma
HIV level was nearly tenfold lower (2,800 cpm), and the
usual ∆plasma:CSF was reversed despite acellular CSF.
While he was prescribed nelfinavir, abacavir and zidovu-
dine, it was suspected that he was not consistently taking
full dosage, and genotypic resistance studies showed no
evidence of significant resistance-associated mutations in
the HIV PR or RT regions (not shown).
Longitudinal treatment studies
Longitudinal analysis involved 28 subjects who were fol-
lowed with repeated LPs after initiating or modifying
treatment. This is an extension of our earlier published
study, adding 13 subjects and prolonging the period of
follow-up for several of the 15 subjects previously
described [25]. Twenty of these subjects were either treat-
ment-naïve, had limited ART exposure, or had been fully
suppressed in the past before stopping therapy and were
therefore anticipated to respond well to ART. The remain-
ing eight subjects had failed their previous treatment and
were either changing therapies or restarting ART after a
hiatus, with addition or substitution of one of more drugs
at entry into the study.
Subjects underwent multiple LPs (median 6, IQR 5–8).
Figure 3 shows the course of their HIV RNA levels in
plasma (A) and CSF (B) along with changes in CSF WBCs
(C) during the follow-up. At baseline, the plasma VLs
were both higher and within a narrower range than those
of CSF.
Early-phase CSF virological responses
The graphs in Figure 3 are divided into 3 temporal seg-
ments. Visual comparison of the initial segment (days 0–
Responses to ARTFigure 3
Responses to ART. The panels show the individual subject 
plots of changes in the plasma (A) and CSF (B) HIV RNA 
concentrations and (C) WBC counts after treatment with 
the time axis broken into three segments showing initial, 
intermediate and longer-term outcomes.
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BMC Infectious Diseases 2005, 5:98 http://www.biomedcentral.com/1471-2334/5/9811) suggests that early viral decay was slower in CSF than
in plasma for some subjects. Using previously described
methods that apply linear regression to the log10 HIV RNA
values in CSF and plasma [25], and restricting comparison
to subjects who began multidrug regimens and exhibited
rapid initial plasma decay, we derived CSF:plasma decay
ratios in 18 of the subjects who had at least 3 LPs between
days 0 and 11.
The CSF:plasma HIV decay ratios were variable (median
0.82, IQR 0.41–1.10). Exploration of the relationship of
these ratios to baseline variables showed a high correla-
tion with only the blood CD4 T lymphocyte count (p <
0.000, rho -0.744), and that neither the baseline VLs
themselves, the CSF WBCs, nor the ADC stage had a sig-
nificant effect. Figure 4 shows the relationship between
the CSF:plasma viral decay ratio and the baseline CD4
counts and includes a regression line that shows equal
decay in plasma and CSF (a CSF:plasma decay ratio value
of 1) near CD4 = 250 cells/µL, with slower decay at lower
CD4 counts. This decay difference related to CD4 count
suggests a change in the character of CSF infection with
more advanced systemic infection.
Longer-term virological and WBC responses in CSF
Despite slower initial decay in CSF compared to plasma in
some subjects, the longer-term effects of ART on CSF HIV
RNA in this group were excellent, and all subjects reached
or approached the limit of detection over the period of
observation (Figure 3A and 3B). As shown in Figure 3C,
treatment also eliminated the CSF pleocytosis in all sub-
jects with elevated baseline WBC counts.
Particularly notable in the treatment group were five sub-
jects who achieved CSF HIV suppression despite persistent
plasma viremia. Their CD4 counts were similar to the
larger group (median 205 cells/µl, range 77 – 269). Four
were neurologically normal, while the fifth (subject 5007)
had a diagnosis of ADC based on longstanding and clini-
cally static myelopathy. The plasma and CSF HIV and
WBC changes for these five subjects with dissociated longer-
term responses are shown in Figure 5 (upper panels), along
with results of phenotypic resistance testing for the drugs
that they were taking (lower panels). The antiretroviral
medication histories and genotypic resistance mutations
detected in the two fluids of these five subjects are pre-
sented in Table 2 [see Additional file 1]. All were treat-
ment-experienced when entering the study; three (4001,
5001 and 5007) were on therapy and changing or modi-
fying their regimens, while the remaining two (4015 and
4030) were off ART at the study start and were initiating
new regimens.
The results of genotypic and phenotypic drug resistance
analysis of plasma and CSF indicate that persistent plasma
viremia was associated with drug resistance that was either
demonstrable at baseline (subjects 4001, 5001 and 5007)
or emerging during the period of observation (4015 and
4030). In two subjects (5001 and 5007) with baseline
resistance, minor differences in genotypic mutations sug-
gested at least partial compartmentalization, with CSF
viruses more drug-susceptible than the predominant
plasma quasispecies. Phenotypic drug susceptibility test-
ing in Subject 5001 (Figure 5B) showed resistance to
drugs in his regimen in both compartments, including
resistance to abacavir. Minor differences in resistance
mutations in the two fluids (Table 2 [see Additional file
1]) were likely insufficient to explain his greater CSF
response. Genotypic analysis in Subject 5007 (Table 2 [see
Additional file 1]) suggests a mixed population of drug
susceptible and resistant viruses in CSF samples (for
example M41M/L, L74L/V and T215T/N/S/Y) compared
to a predominantly resistant population in plasma (for
example M41L, L74V and T215Y). Perhaps greater suscep-
tibility of a 'compartmentalized' CSF virus population
contributed to the greater CSF response (Table 2 [see
Additional file 1] and Figure 5C). Interestingly, the highly
resistant plasma HIV population did not 'overflow' into
the CSF and completely alter its resistance profile.
Relation of CSF:plasma early-phase decay ratio to baseline blood CD4 cell countsFigure 4
Relation of CSF:plasma early-phase decay ratio to baseline 
blood CD4 cell counts. The regression line and 95% confi-
dence intervals were plotted after censoring one subject with 
CD4 = 1,140 cells/µL. The p-value and r2 of this regression 
analysis are shown on the figure, while the results of nonpar-
ametric analysis are discussed in the text. The horizontal 
broken line designates the point at which plasma and CSF 
decay are equal (ratio of 1) and the vertical broken line sig-
nals the point where this crosses the regression line – near a 
blood CD4 count of 250 cells/µL.
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BMC Infectious Diseases 2005, 5:98 http://www.biomedcentral.com/1471-2334/5/98The other three (4001, 4015, and 4030) showed no evi-
dence of compartmentalization at baseline, with similar
susceptibility in both plasma and CSF virus populations.
In Subject 4001 (Figure 5A), high-level resistance to lami-
vudine, saquinavir and ritonavir raises the question of
whether the therapeutic effect on CSF may have related
principally to stavudine, though this drug was insufficient
to suppress plasma HIV. The initial samples of both
plasma and CSF from Subject 4015 (Figure 5D) showed
mixed populations of lamivudine resistance (M184M/V),
from which emerged the resistant quasispecies (M184V)
at the time of viral rebound (Table 2 [see Additional file
1]). In Subject 4030 (Figure 5E) phenotypic and genotypic
resistance testing showed nearly identical susceptibility in
CSF and plasma, and wild-type genotypes in both com-
partments. At day 85 and afterwards, his plasma HIV
showed increasing resistance to lamivudine, nelfinavir
and efavirenz (resistance to nevirapine increased simi-
larly, not shown), with susceptibility only to stavudine,
though genotyping showed the emergence of a stavudine
mutation, T215Y. In addition to the disproportionate CSF
HIV response, CSF WBC counts were also suppressed in
these subjects. This was most remarkable in subjects 4015,
with more than 45 cells/µL, and 5001, with 33 cells/µL at
baseline; in both, the pleocytosis resolved despite sus-
tained plasma HIV.
Neurological responses to ART
In the 24 treatment-group subjects without active ADC at
baseline, QNPZ-4 scores were stable or showed small
increases over the course of observation (not shown). The
four subjects in the treatment group who presented with
active ADC (5002, 4033, 4013, and 4034) showed both
clinical improvement and distinct increases in this per-
formance score in response to initiation or change of
antiretroviral therapy. The clinical histories, antiretroviral
therapy regimens, laboratory measurements, and QNPZ-4
scores of these subjects are presented in Figure 6. Of note,
genotypic resistance testing, available at baseline for Sub-
ject 4034 (Figure 6D) who developed ADC on treatment
with an unusual regimen, showed concordance in CSF
and plasma with no resistance mutations in the RT and
only L63P, A71A/V and V77I changes in the PR. These
findings are consistent with insufficient drug potency and
poor drug penetration into the CSF, and might suggest
that the CNS served as a major site of viral replication in
this subject. In response to a change to abacavir, nevirap-
ine and indinavir/ritonavir, he achieved virological sup-
pression in both and an improvement in the speed and
clarity of his cognition.
Discussion
The CSF found in the ventriculo-leptomeningeal space is
separated from systemic sources of virus, immune
defenses, and antiviral drugs, and is easily sampled by
lumbar puncture. Thus, study of CSF HIV infection can
serve a valuable role in understanding the dynamics and
mechanisms of infection within an isolated tissue com-
partment. Further, CSF infection serves as both a model of
and window into brain infection, providing important
insight into viral neuropathogenesis. This CSF 'compart-
ment' can be viewed as parallel to the brain compartment,
sharing some of its barrier features. However, exchanges
between CSF and blood may differ from those between
brain and blood, and as a result, tissue responses may dif-
fer from CSF responses in important ways [27]. More
Dissociated CSF and plasma HIV RNA responses in five subjectsFigure 5
Dissociated CSF and plasma HIV RNA responses in five subjects. Each of these subjects achieved near or full CSF viral suppres-
sion despite an incomplete plasma response. The top panels of each pair show CSF and blood HIV RNA and CSF WBC values 
(A). The lower panels graphically depict the phenotypic resistance profiles as fold change in susceptibility to the drugs these 
subjects were taking during the study compared to reference wild type on a log10 scale [26]. See the text for discussion.
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BMC Infectious Diseases 2005, 5:98 http://www.biomedcentral.com/1471-2334/5/98directly, the CSF may reveal brain processes as a conse-
quence of its intimate contiguity and function as an extra-
cellular 'sink' where molecules produced in the brain (or
along its perivascular spaces) that have diffused into the
CSF can be sampled [8].
The studies described here used complimentary cross-sec-
tional and longitudinal approaches to show that CSF
infection is a nearly universal facet of the ecology of sys-
temic HIV infection. CSF HIV RNA concentrations corre-
lated with those of plasma, but were characteristically
lower. The median difference between plasma and CSF
HIV VLs (∆plasma:CSF) was 1.30 log10 cpm though this
difference also varied considerably, ranging from -1.32 to
4.08 log10 cpm. Our results extend previous reports
[4,6,7,28-31] and focus on the factors that modify CSF
infection in relation to plasma VL. CSF infection is impor-
tantly influenced by the CSF WBC response, the degree of
systemic immunological progression as measured by
blood CD4+ T cells, antiretroviral treatment and drug
resistance, and the presence of active ADC.
CSF WBCs
CSF WBC counts were commonly elevated in this series,
confirming findings reported earlier in the epidemic (e.g.,
[2]). Our steady-state cross-sectional and treatment-
related longitudinal observations confirm that this CSF
pleocytosis is directly linked to HIV infection itself, rather
than to another cause such as undiagnosed opportunistic
infection. Specifically, the cross-sectional analysis showed
Longitudinal follow-up of four subjects presenting with new-onset or progressing ADCFigure 6
Longitudinal follow-up of four subjects presenting with new-onset or progressing ADC. The upper panel of each pair shows 
the plasma and CSF VL responses along with CSF WBC changes, and the lower panels show treatment effects on the QNPZ-4 
scores and the blood CD4 counts. The table below each graph indicates clinical features of each respective subject. Antiretro-
viral medications considered able to penetrate the CSF [10] are indicated in bold font. The key to the symbols for all graphs 
are shown to the left of panel set (A).
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BMC Infectious Diseases 2005, 5:98 http://www.biomedcentral.com/1471-2334/5/98that CSF WBC counts were highly correlated with CSF HIV
RNA concentrations (Figure 2) though not with the
plasma VL. A similar association of CSF HIV with CSF
WBC count has previously been reported by several
groups [32,8,33]. The longitudinal studies of treatment
indicated this association even more clearly, revealing res-
olution of baseline pleocytosis in all those beginning ART
(Figure 3C). This association is also supported by our pre-
vious report that about half of subjects undergoing STI
develop a brisk CSF pleocytosis upon stopping therapy
[14].
While this combined experience indicates that CSF VLs
and WBC counts are related, it begs the fundamental
mechanistic question of whether the CSF WBCs actually
contribute to raising the CSF VL, or alternatively, represent
only a response to high CSF virus. We discuss these two
alternative hypotheses in relation to models of CSF infec-
tion below.
Change in the character of CSF infection with disease 
progression
Two of the observations reported here show a change in
the relation of CSF infection to systemic infection as the
latter progresses (as indicated by reduction in blood CD4
lymphocyte counts). First, in the cross-sectional study the
∆plasma:CSF values in subjects with CD4 counts below
50 cells/µL (the first CD4 quartile of the group) were sig-
nificantly larger than those of the remaining subjects with
more preserved CD4 counts. This was related to higher
plasma VLs, but without concomitant increase in CSF VLs;
rather CSF VLs for these subjects were similar to those of
the remaining subjects. This quartile also had lower CSF
WBC counts. This observation confirms the impression of
earlier investigators that CSF cell counts decrease in those
with more advanced systemic infection [2]. We discuss
later how these two observations, higher ∆plasma:CSF
and reduced CSF WBC counts, might be linked.
The second difference was in the rates of viral decay dur-
ing the initial phase of therapy in CSF compared to
plasma. Viral decay in CSF was slower than in plasma in
subjects with lower CD4 counts, while decay rates in the
two fluids were more often equal at higher CD4 counts.
This finding extends our earlier report of this association
[25]. It agrees, in part, with the findings of Ellis and col-
leagues [34] of a similar CD4 effect in a smaller series.
However, this association of early decay differences with
CD4 counts is at variance with a report by Eggers and col-
leagues [35] who correlated slower CSF decay after ther-
apy with the presence of ADC or HIV encephalitis. Indeed,
our results suggest that slower CSF decay was not confined
to ADC subjects, but also occurred in neurologically
asymptomatic subjects with low CD4 counts as noted by
Ellis et al [34]. Further elucidation of these associations
and the reasons for the minor differences in the experi-
ences of different research groups will require a larger,
more varied population sample, or combined analyses of
the experience from several centers. Whatever the precise
association, these observations suggest that the character
of CSF infection changes with disease progression. In
those with less advanced systemic disease, CSF infection
often responds to potent ART as rapidly as blood infec-
tion. In those with more advanced systemic disease, with
or without ADC, CSF HIV responds more slowly to antivi-
ral therapy.
Overall effects of ART on CSF HIV infection
Before undertaking this study, we were concerned that
CSF infection might not respond as well as systemic infec-
tion to treatment because of restricted penetration of
many antiretroviral drugs [10]. This was not borne out by
our observation that combination ART had a favorable
impact on CSF HIV infection in the population of treated
subjects. In the cross-sectional sample, both the plasma
and CSF VLs were higher in untreated (median 4.93 and
3.61 log10 cpm in plasma and CSF, respectively) than in
treated (median 4.00 and 1.66 log10 cpm in plasma and
CSF) subjects (p < 0.001 for both variables compared by
t-test). As noted also, HIV RNA was below the detection
limit in a greater proportion of the CSF (38.9%) than
plasma samples (18.5%). Given that the CSF HIV
responded to therapy at least as effectively as plasma HIV,
a relatively impaired CSF penetration of antiretroviral
drugs seems unlikely to have influenced our findings.
However, we did compare the CSF penetration of the
antiretroviral regimens between those 'failing' to achieve
virological suppression in plasma, and those with viral
suppression, using a summed score in which each drug
known to penetrate CSF counted as one and those not
penetrating well counted as zero (data not shown). The
means of the summed scores in the two groups (1.86 +/-
0.93, and 2.33 +/- 1.19, respectively) were not signifi-
cantly different (p = 0.115). Of note, high CSF HIV was
noted in rare treated subjects, sometimes exceeding
plasma levels, as in subject 4034 who was treated with an
unusual, poorly CSF-penetrating drug regimen [36] but
responded well to an altered regimen. A second example
of higher CSF than plasma HIV was subject 4032 who was
suspected to be poorly adherent to his medications; geno-
typic testing supported this hypothesis by showing that
his treatment failure was not due to drug resistance. Thus,
although classified as on therapy, he likely was on inter-
mittent and ineffective ART at best [37]. Overall, our expe-
rience suggests that effective CSF viral suppression is the
general rule when plasma virus is suppressed.
The effectiveness of ART was clearly evident in the longi-
tudinal treatment series. While the initial rate of CSF HIV
decay lagged behind that of plasma in some subjects, allPage 11 of 19
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BMC Infectious Diseases 2005, 5:98 http://www.biomedcentral.com/1471-2334/5/98those with long-term follow-up achieved gratifying HIV
reduction in this compartment with a time course gener-
ally proportional to their baseline level (Figure 3). None
of the 28 patients showed persistent CSF virus in the face
of undetectable plasma VL. The responses in subjects
without previous treatment were similar to those reported
by Polis and colleagues [30]with a protracted course but
excellent suppression at 6 months. Our results also corre-
late well with the longer-term outcomes in more heteroge-
neous cohorts reported by others [38,39,35].
Effect of treatment of CSF infection in the presence of 
drug resistance
In addition to the generally favorable effects of ART on
CSF infection, we observed an intriguing, salutary facet of
treatment response. Namely, CSF infection showed a pro-
portionally greater response to treatment than plasma
infection in the face of antiviral drug resistance. Since drug
resistance is the principal reason for long-term treatment
failure, this may have very important implications for the
prevention and treatment of CNS HIV infection and ADC.
This superior effect of ART on CSF infection was noted in
both the cross-sectional study and in the longitudinal
treatment study. Moreover, it had been anticipated in our
previous observations of CSF rebound in subjects with
virological failure who underwent STI [18].
To examine this issue in the cross-sectional group, we
compared the 36 subjects who were on therapy but had
plasma VLs above 500 cpm (defined as treatment failures)
with the 46 untreated subjects. While these two groups had
similar plasma VLs (median 4.73 log10 cpm, IQR 3.99 –
5.04 in the treatment failure group, and 4.93 log10 cpm,
IQR 4.53 – 5.48 in the untreated; p = 0.072 by t-test), their
CSF HIV RNA levels differed substantially (2.45 log10 cpm
median, IQR 1.45 – 3.64 log10 cpm in the treatment fail-
ure group, and 3.61 median, IQR 2.57 – 4.40 in the
untreated; p = 0.002). As a result, the ∆plasma:CSF was
about ten-fold higher in the treatment failure (median,
2.19 log10 cpm, IQR 1.90 – 2.58) than in the untreated
group (median 1.18 log10 cpm, IQR 0.42 – 2.16; p =
0.025); this 100-fold difference between plasma and CSF
was similar to that reported by Stingele and colleagues in
a study of paired specimens evaluating resistance muta-
tions [29]. Thus, 'treatment failure' in the cross-sectional
group was often associated with proportionally greater VL
reductions in CSF than plasma.
This effect was further illustrated in the 'dissociated' CSF
responses of the five treatment subjects who failed to clear
virus in the plasma but responded completely or nearly
completely to treatment in the CSF (Figure 5, Table 2 [see
Additional file 1]). Their CSF HIV responses were both
proportionally greater and more prolonged than those of
plasma. Analysis of drug susceptibility in these 5 subjects
showed that the main reason for continued plasma
viremia was drug resistance. At least two patterns of
responses were noted: 1) resistance at baseline leading to
an initial small reduction in viremia and a new plateau
(subjects 4001, 5001 and 5007, who switched medication
at the start); and 2) a greater initial response followed by
later partial recrudescence (subjects 4015 and 4030 who
had been off therapy for some time after treatment failure
before starting back on a new regimen). In the first two
subjects, resistance was well established at baseline, while
in the second two it emerged during the study, presuma-
bly from archived resistant strains [40]. Subject 5007 (Fig-
ure 5C) may have had a greater degree of
compartmentalization of resistant virus. Genotypic test-
ing revealed a plasma viral population with resistance-
associated mutations at several amino acid sites (e.g., Pro-
tease mutation L90M and Reverse Transcriptase muta-
tions M41L, K103N, Y181C, and T215Y). Testing of the
CSF viral population revealed mixtures of wild-type with
resistance-associated amino acids at all these sites. Such
compartmentalized resistance with differences in drug
susceptibility between CSF and plasma clearly occurs
[41,29,42]. Notably, however, in the context of such sys-
temic and CSF resistance, ART can be proportionally more
effective in suppressing CSF infection than in treating sys-
temic infection.
In fact, this greater effect on CSF than plasma in the face
of drug resistance and treatment failure was predicted by
observations on subjects failing ART who undertook STI
[14,18]. In some of these subjects, the baseline CSF VLs
were 10- to 1000-fold lower than baseline plasma VLs, but
upon STI, rose to levels near or equal to those of plasma,
indicating that the 'failed' therapy had suppressed the HIV
to a greater extent in CSF than in plasma.
Models of blood-CSF virus and cell exchange and 
compartmentalization
To conceptualize CSF changes during infection, we
framed 2 simple models of the exchange of HIV and lym-
phocytes between the blood and CNS compartments
[9,14]. Figure 7 provides a schematic diagram of the ele-
ments of this model and examples of the variable relation-
ships of CSF to plasma HIV noted in different clinical
settings. The model invokes two basic types of infection:
transitory and autonomous, as pictured in Panels A and B
of Figure 7.
Transitory infection (Figure 7A) refers to infection sustained
by short-lived CD4+ T cells trafficking into the CSF space
from the blood. In simplified terms, activation of lym-
phocytes outside of the nervous system favors their pro-
miscuous entry [43,27], and when infected by HIV, these
activated CD4 cells can release HIV into the surrounding
fluid. This type of infection is determined principally fromPage 12 of 19
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BMC Infectious Diseases 2005, 5:98 http://www.biomedcentral.com/1471-2334/5/98outside of the CNS, and depends upon systemic infection
and cell activation. Infected and uninfected cells are
pushed into the CSF.
Autonomous infection (Figure 7B) refers to infection that is
sustained within the CNS by longer-lived cells and does
not require continuous repletion from the blood. This is
the type of infection that is also assumed to be 'compart-
mentalized' [44] and is likely sustained by longer-lived
cells of the monocyte lineage that assume residence as
perivascular and meningeal macrophages [45] rather than
trafficking lymphocytes [46]. Whether such infection is
fully self-sustaining or requires renewal from outside
remains uncertain [47], but in it, the rates of turnover are
Model of CSF HIV infectionFigure 7
Model of CSF HIV infection. The diagram provides a simple schematic of hematogenous infection with T cells (including HIV-
infected CD4 cells) and intrathecal macrophages separated by the blood-brain endothelial barrier. The model presumes that 
virus reaches the CNS principally within infected cells. T cells are shown as round cells, either infected (bar within nucleus) or 
uninfected (no bar). Similarly, the macrophages are shown as flat, elongated cells with or without infection (again, bar in 
nucleus). Both virus (circles with central dot) and cytokine/chemokine (smaller solid circles) are produced or provoked by 
infection on both sides of the barrier. Cells particularly involved in the illustrated process are highlighted in red and also may 
show thickened outline when active and broken line when the action is attenuated. Panels A, B, and C presents a simplified 
schematic of two basic types of CSF infection, transitory and autonomous, along with a combination of these types in mixed or 
amplified infection. Panels D-G apply these models to the relationships of plasma and CSF HIV (∆plasma:CSF) in four of the set-
tings described in this report, including D. the high ∆plasma:CSF in subjects with pleocytosis >10 cells/µL related to exuberant 
transitory infection; E the high ∆plasma:CSF in ADC patients due to enhanced autonomous infection; F. the low ∆plasma:CSF 
in subjects with < 50 blood CD4 cells/µL related to reduced transitory infection; and G the low ∆plasma:CSF in treatment fail-
ures also related to decreased transitory infection.
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BMC Infectious Diseases 2005, 5:98 http://www.biomedcentral.com/1471-2334/5/98lower and the cellular pools are different from those of
transitory infection. When accompanied by CSF pleocyto-
sis, the reactive cells are pulled into the CSF space [48].
Both of these basic types of infection may occur simulta-
neously or sequentially, and indeed mixed infection with
varying contributions of the two types may be the rule
(Figure 7C).
We hypothesize that transitory infection predominates dur-
ing the early phases of systemic HIV infection but gives
way to an increasing component of autonomous infection as
immune deregulation progresses. One reason for hypoth-
esizing the early predominance of transitory infection is
that the rapid, early-phase decay of CSF HIV RNA noted in
some subject initiating therapy is equivalent to that occur-
ring in the plasma. The rate of plasma HIV decay depends
upon the potency of the antiviral regimen [49], and as
drug exposure in the CNS is almost always lower than at
most systemic sites (by virtue of the blood-brain and
blood-CSF barriers and other factors reducing drug pene-
tration), we would expect the potency of the regimen in
CSF VL to be lower. However, incorporating a model of
transitory CSF infection, suppression of systemic infection
would also lower the infection rate of trafficking lym-
phocytes and virus-induced activation, thereby reducing
the influx of these cells and rapidly decreasing the CSF VL.
Evolution from transitory to more autonomous infection at
later stages of disease would explain the slower CSF decay
relative to plasma, as decay kinetics are now closely asso-
ciated with reduction in T cells. CSF infection may also be
amplified by entry of activated infected or target CD4 cells
which increase their transit across the endothelial barrier
in response to chemokines and other signals (Panel C of
Figure 7). Amplified infection might obscure the underlying
importance of autonomous infection as the inciting proc-
ess, and might respond more readily to systemic treat-
ment.
Variations of these models can also be invoked to explain
the relationships of CSF to plasma VL noted in some of
the subject groups in this study. For example, the two sit-
uations where we found smaller ∆plasma:CSF. values
might relate to quite different mechanisms. Specifically,
in the first instance the association of pleocytosis (>10
cells/µL) with high CSF HIV RNA (approaching that of the
plasma VL with both ≥ 10,000 cpm), and small
∆plasma:CSF might relate to exuberant cell entry and a
high level of transitory or amplified infection as dia-
grammed in Figure 7D. This mechanism would also
account for high CSF HIV concentrations in patients with
meningitis due to other infections such as Mycobacterium
tuberculosis and Cryptococcus neoformans [4,50], where cell
entry is driven by an unrelated process but result in local
amplification of CSF infection. In the second instance,
narrow or even reversed (negative) ∆plasma:CSF is best
explained by a high level of autonomous infection within
perivascular or parenchymal macrophages in patients
with ADC (Figure 7E).
Figure 7 also illustrates hypothetical explanations for the
increased ∆plasma:CSF noted in two settings: subjects
with CD4 counts < 50 cells/µL (F) and those with treat-
ment failure (G). In both cases, a diminished transitory
component of infection may be involved, either because
of insufficient CD4 target cells or reduced signals and
responses to cell activation. In the case of low CD4 cells,
the reduced transitory component uncovers low-level
autonomous CSF infection. Of course, comparison of this
setting with ADC in which CD4 cells are often decreased
underscores a switch from low-level and seemingly
benign autonomous infection to more active and 'malig-
nant' macrophage infection with resultant toxic sequelae.
This then raises the question of what causes the change in
the character of autonomous infection in this setting – a
change in the virus population or an alteration in the
host? The increased ∆plasma:CSF in treatment failure is
supported by observations of diminished cell activation
in this setting [51], but is this sufficient to reduce CSF HIV
to the extent observed? Might reduced activation and
lower CSF HIV levels relate to reduced fitness of the resist-
ant viruses [52] or simply to a quantitative decrement in
systemic infection?
These considerations also do not fully preclude the impor-
tance of intrathecal drug effects. Simply considering extra-
cellular drug levels in CSF compared to plasma may not
be sufficient. Intracellular drug activity of nucleoside RT
inhibitors might be enhanced within the cells supporting
autonomous CNS infection despite lower extracellular
drug concentrations than in systemic sites of infection
[53]. Subject 4034, with disproportionate virological fail-
ure in CSF compared to blood in the face of a poorly pen-
etrating ART regimen, illustrates the potential importance
of drug penetration in the presence of autonomous infec-
tion. His high CSF VL was remedied by a regimen with
greater penetration.
Neurological implications
These studies have relevance for two clinical neurological
disorders related to CNS HIV infection: aseptic meningitis
and ADC. The first is a component of the central focus of
the study, while the second stands as an important back-
ground issue.
Aseptic or HIV meningitis is the clinical diagnosis conferred
on HIV-infected patients with CSF pleocytosis without
alternative cause, irrespective of clinical symptoms or
signs such as headache, photophobia and stiff neck [54-
56]. We extend the characterization of this aseptic menin-
gitis, defining its virological profile, clinical context andPage 14 of 19
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pleocytosis was detected in those with CD4 counts above
50 cells/µL, and was associated with plasma VLs near or
above 10,000 cpm.
The frequency of pleocytosis in our subjects and their lack
of symptoms confirms earlier observations reported at a
time when HIV infection was less well characterized [2,3].
Our subjects were queried and assiduously examined for
symptoms or signs of meningitis, and tested for associated
abnormality or changes in QNPZ-4. None were found,
and we were unable to predict the presence of elevated
WBC counts from interviews or examinations. Why is
HIV-associated pleocytosis asymptomatic when other
infections with similar CSF cell counts are often accompa-
nied by clinical symptoms and signs? Presumably, there
are differences in the character of the cells, and more par-
ticularly in their secreted products, that determine the
absence or presence of symptoms.
Since CSF pleocytosis is frequent and characteristically
asymptomatic, how does one approach the HIV-infected
patient presenting with headache who has an elevated
CSF lymphocyte count [56]? When is pleocytosis inciden-
tal and headache due to another cause? When can pleocy-
tosis be attributed to the underlying HIV infection and
thus not warrant further diagnostic evaluations? Our
experience allows some initial answers to these questions.
First, pleocytosis related only to HIV is uncommon in
those with blood CD4 counts below 50 cells/µL, and
therefore an increased CSF cell count in this setting should
be suspect. Second, since ART usually eliminates elevated
WBC counts, pleocytosis in a treated patient should be
regarded similarly, with the additional consideration of
adherence to therapy. Third, since headache is rarely pro-
voked by simple HIV-related pleocytosis, a search for
another type of CNS infection or process is warranted in
such a case. Finally, in chronic pleocytosis without head-
ache, a trial of ART may confirm HIV as the cause if the cell
count resolves. Perhaps the term aseptic meningitis in this
setting should be reserved for those with symptoms or
signs accompanying CSF abnormalities. The larger group
of individuals with clinically silent elevated CSF cell
counts may simply be designated as having asymptomatic
pleocytosis of HIV infection.
ADC is considered to be caused by brain HIV infection,
but mediated by 'indirect' mechanisms involving a variety
of pathways initiated and sustained by viral and host gene
products [57-61]. Infected and uninfected macrophages
and perhaps microglia appear to play a central role in
these processes [45]. The current study focused on CSF
HIV infection and was not designed to more directly
assess the relationship of parenchymal brain HIV infec-
tion to ADC. Nonetheless, it afforded a view of certain
aspects of this important issue.
Neurological performance was assessed using the QNPZ-
4 score. This correlated highly with the presence and stage
of ADC; the reduced QNPZ-4 score (median -0.50) of the
cross-sectional sample was largely the result of including
the ADC subjects. Longitudinally, the QNPZ-4 score
afforded a stable measure in those without change in clin-
ical neurological status, while it tracked a pattern of
improvement in ADC subjects responding to ART that
mirrored their antiviral response in CSF and plasma (Fig-
ure 6). Cross-sectionally, both ADC stages and QNPZ-4
scores correlated with blood CD4 counts, though neither
correlated overall with plasma or CSF HIV RNA levels. The
association of ADC with HIV progression and depressed
CD4 blood counts has been well documented [62], and
the lack of correlation of neurological disease with the
magnitude of systemic or CSF infection over the broad
range of CD4 counts has also been previously noted [6,7].
Our findings agree with some [8] but differ from other
reports [7] in that we also did not find a strong correlation
between the neurological and virological measurements
in subjects with lower CD4 counts. There was only a weak
correlation between CSF VL and ADC stage (p = 0.037,
rho = 0.316) in subjects with CD4 counts below 200 cells/
µL, and no significant correlation with QNPZ-4 score in
this group; no correlation of the CSF HIV concentration
with ADC stage or QNPZ-4 score was found in subjects
with CD4 counts <50 cells/µL. Moreover, we found no
correlation between the neurological measures and CSF
VLs among the entire group of untreated subjects, or in
those with CD4 counts below 200 cells/µL.
This does not mean that HIV brain infection is not central
to the pathogenesis of ADC or that HIV brain infection
cannot be reflected in CSF, but only that such an associa-
tion is obscured by other factors. In this study, there may
have been two principal reasons why no association was
found. First, there was a high 'background' of increased
CSF HIV in neurologically normal subjects. Second, many
of our ADC subjects were on ART and clinically stable,
and therefore likely suffered 'inactive' or residual brain
disease. The lack of diagnostic specificity of CSF HIV RNA
measurements underscores the varied relationship
between CSF changes, on the one hand, and brain infec-
tion and disease, on the other. The CSF space and brain
parenchyma are best viewed as two separate but intersect-
ing compartments in which infection is not always con-
gruent, necessitating caution in interpreting brain events
from CSF findings. At least three types of intersections
may occur. First, brain infection can 'overflow' into the
CSF so that brain-derived HIV (and other markers) can be
detected and directly measured in this fluid. The likely
major cells of origin for HIV in these cases of autonomousPage 15 of 19
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parenchymal macrophages and microglia [45], with virus
reaching the CSF by diffusion along the perivascular
spaces. CSF in this setting can provide a direct sample of
brain infection. Second, CSF and brain infection may be
parallel, although not necessarily identical. Because the
leptomeninges and brain are both non-lymphatic organs
and separated from the blood by barriers to the free pas-
sage of viruses, immune defenses (both humoral and cel-
lular) and drugs, infection and host responses may be
sufficiently similar in the meninges and brain to permit
CSF analysis to monitor brain infection, whether autono-
mous or transitory. Third, infections might markedly
diverge in these compartments, in which case CSF would
provide little direct insight into brain infection; at the
extreme, the CSF might simply reflect meningeal infection
which has no counterpart within the brain. The problem
for the clinician is to distinguish which of these three rela-
tionships predominates in a given patient.
Measuring the VL in CSF is not enough to make these
important distinctions, and the CSF HIV RNA concentra-
tion cannot, in isolation, serve as a reliable diagnostic
marker for ADC. Nor can the presence of pleocytosis be
used to rule in or out ADC. This is unfortunate since
objective markers are needed both in the clinic for practi-
cal diagnosis and in the research setting to more precisely
define therapeutic targets. In the occasional patient, such
as those designated as outliers in Figure 2, substantially
higher HIV RNA in CSF than in plasma may be diagnosti-
cally suggestive, but in most cases neither the level of CSF
virus nor its relation to the plasma VL distinguishes those
with ADC. Future efforts need to assess the value of sup-
plementary CSF measurements, involving more detailed
characterization of the virus (cell tropism, chemokine co-
receptor utilization, or still-elusive markers of neuropath-
ogenicity) [63-65] along with the use of ancillary markers
of immune responses and neural injury [8,66,67].
An additional clinical need is for laboratory measures that
assess the activity of ADC and underlying HIV encephali-
tis. While we included subjects in this study with treated
ADC and suppressed CSF infection, this would not be
appropriate in a clinical trial assessing ADC treatment.
Measuring CSF HIV concentration may be helpful in this
setting, since undetectable CSF HIV likely signals sup-
pressed brain infection.
Conclusion
HIV infection of the CNS is a nearly ubiquitous facet of
systemic infection, but varies in character and clinical con-
sequences. From very early exposure during primary sys-
temic infection, most HIV-infected patients experience
chronic asymptomatic CNS infection. However, a few
individuals will develop encephalitis presenting as ADC.
CSF sampling provides a valuable window into this infec-
tion and its variability.
We have framed the discussion of our results in models of
CSF infection. Embedded in these models are a number of
dichotomies relating systemic to CNS infections: (1) tran-
sitory versus more autonomous infections with rapid versus
slower turnover rates; (2) CSF lymphocytosis either caus-
ing or responding to local infection, and (3) infection of the
meninges presenting as 'asymptomatic pleocytosis' versus
more toxic parenchymal or perivascular infection leading
to the brain dysfunction of ADC. These provide a frame-
work for future studies examining the mechanisms of
infection in molecular terms and with respect to cell and
HIV exchange and compartmentalization.
On a more practical level, to the extent that CSF infection
reflects infection of the brain, antiretroviral therapy is usu-
ally effective in suppressing CNS HIV replication. Our
longitudinal observations show that CSF infection usually
responds well to combination antiretroviral therapy,
equaling or exceeding systemic responses as reflected in
plasma. Even where resistance leads to virological failure
and persistent plasma viremia, ART may have a salutary
effect on CSF. While the mechanisms underlying these
favorable treatment effects remain uncertain, these obser-
vations are consonant with other reports using less fre-
quent monitoring and are therapeutically reassuring. Our
findings suggest that favorable virological outcomes in the
CSF are the rule rather than an exception. They are also
consistent with clinical studies that report a falling inci-
dence of ADC in the current treatment era [68].
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